The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Alliance A091102: Phase II study of MLN8237 (alisertib) in advanced/metastatic sarcoma.
Mark Andrew Dickson
No relevant relationships to disclose
Michelle R. Mahoney
No relevant relationships to disclose
Benjamin T. Marchello
No relevant relationships to disclose
Mercedes M. Condy
No relevant relationships to disclose
William D. Tap
No relevant relationships to disclose
Gary K. Schwartz
No relevant relationships to disclose